Multicenter, double-blind, randomized, placebo-controlled, parallel group study to assess the efficacy, safety, and tolerability of tezosentan in patients with acute heart failure

Trial Profile

Multicenter, double-blind, randomized, placebo-controlled, parallel group study to assess the efficacy, safety, and tolerability of tezosentan in patients with acute heart failure

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Tezosentan (Primary)
  • Indications Acute heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms VERITAS-1
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 10 Mar 2017 Results of value of endothelin receptor inhibition with tezosentan data from VERITAS studies published in the European Journal of Heart Failure
    • 13 Sep 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top